Department of Hematology, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuhang District, Wuhan, 430071, P. R. China.
Wuhan United Pharmaceutical Co., Ltd., Wuhan, 430071, P. R. China.
Chem Biodivers. 2021 Jun;18(6):e2100139. doi: 10.1002/cbdv.202100139. Epub 2021 May 11.
Shengxuening (SXN) is a Chinese patent medicine with main ingredients (including chlorophyll derivatives and sodium iron chlorophyllin) extracted from silkworm excrement. SXN exhibited efficacy in clinical trials of renal anemia and iron deficiency anemia; however, the specific mechanisms remain unclear. This study found that SXN increased the number of peripheral blood cells and improved the bone marrow morphology in myelosuppressed mouse model, reversed the reduction in body weight and spleen indices, and increased the serum levels of erythropoietin and granulocyte-macrophage colony-stimulating factor. Quantitative real-time PCR array and Western blot analysis showed the enhanced expression of stem cell factor (SCF), JAK2, and STAT3 in the liver. These results suggested that SXN promoted the recovery of hemopoietic function in myelosuppressed models by increasing the secretion of hematopoietic factors and activating the JAK2/STAT3 pathway. Therefore, this medicine may be applied as therapeutic pharmaceutical drug to mitigate myelosuppression.
生血宁（SXN）是一种中药，主要成分（包括叶绿素衍生物和铁叶绿酸钠）从蚕粪中提取。SXN 在肾性贫血和缺铁性贫血的临床试验中显示出疗效，但具体机制尚不清楚。本研究发现，SXN 增加了骨髓抑制小鼠模型外周血血细胞数量，改善了骨髓形态，逆转了体重和脾脏指数的降低，并增加了促红细胞生成素和粒细胞-巨噬细胞集落刺激因子的血清水平。实时定量 PCR 阵列和 Western blot 分析显示，肝脏中干细胞因子 (SCF)、JAK2 和 STAT3 的表达增强。这些结果表明，SXN 通过增加造血因子的分泌并激活 JAK2/STAT3 通路，促进骨髓抑制模型中造血功能的恢复。因此，该药物可能作为治疗药物应用于减轻骨髓抑制。
